Prescient Therapeutics Ltd (PTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Prescient Therapeutics Ltd (PTX) has a cash flow conversion efficiency ratio of -0.386x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-6.54 Million ≈ $-4.63 Million USD) by net assets (AU$16.97 Million ≈ $12.01 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Prescient Therapeutics Ltd worth for the company's overall valuation and market capitalisation.
Prescient Therapeutics Ltd - Cash Flow Conversion Efficiency Trend (1991–2025)
This chart illustrates how Prescient Therapeutics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Prescient Therapeutics Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Prescient Therapeutics Ltd ranked by their cash flow conversion efficiency. Explore PTX cash flow quality score to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SRM Entertainment, Inc. Common Stock
NASDAQ:SRM
|
0.000x |
|
Samhyun Steel Co. Ltd
KQ:017480
|
0.052x |
|
The Hain Celestial Group Inc
NASDAQ:HAIN
|
0.178x |
|
Fanhua Inc.
NASDAQ:AIFU
|
0.117x |
|
Crown Confec
KO:005740
|
0.045x |
|
Klotho Neurosciences, Inc.
NASDAQ:KLTO
|
-0.110x |
|
Itera ASA
OL:ITERA
|
0.475x |
|
Howden Joinery Group Plc
LSE:HWDN
|
0.168x |
Annual Cash Flow Conversion Efficiency for Prescient Therapeutics Ltd (1991–2025)
The table below shows the annual cash flow conversion efficiency of Prescient Therapeutics Ltd from 1991 to 2025. View latest Prescient Therapeutics Ltd stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$11.39 Million ≈ $8.06 Million |
AU$-7.24 Million ≈ $-5.13 Million |
-0.636x | -55.35% |
| 2024-06-30 | AU$18.07 Million ≈ $12.78 Million |
AU$-7.40 Million ≈ $-5.23 Million |
-0.409x | -72.46% |
| 2023-06-30 | AU$26.08 Million ≈ $18.45 Million |
AU$-6.19 Million ≈ $-4.38 Million |
-0.237x | +7.72% |
| 2022-06-30 | AU$16.76 Million ≈ $11.86 Million |
AU$-4.31 Million ≈ $-3.05 Million |
-0.257x | -32.38% |
| 2021-06-30 | AU$20.43 Million ≈ $14.45 Million |
AU$-3.97 Million ≈ $-2.81 Million |
-0.194x | +6.16% |
| 2020-06-30 | AU$11.19 Million ≈ $7.92 Million |
AU$-2.32 Million ≈ $-1.64 Million |
-0.207x | +29.30% |
| 2019-06-30 | AU$14.32 Million ≈ $10.13 Million |
AU$-4.20 Million ≈ $-2.97 Million |
-0.293x | -28.67% |
| 2018-06-30 | AU$9.44 Million ≈ $6.68 Million |
AU$-2.15 Million ≈ $-1.52 Million |
-0.228x | +18.15% |
| 2017-06-30 | AU$11.78 Million ≈ $8.34 Million |
AU$-3.28 Million ≈ $-2.32 Million |
-0.278x | -132.19% |
| 2016-06-30 | AU$13.01 Million ≈ $9.21 Million |
AU$-1.56 Million ≈ $-1.10 Million |
-0.120x | +76.20% |
| 2015-06-30 | AU$4.45 Million ≈ $3.15 Million |
AU$-2.24 Million ≈ $-1.59 Million |
-0.503x | -124.50% |
| 2014-06-30 | AU$5.03 Million ≈ $3.56 Million |
AU$-1.13 Million ≈ $-797.64K |
-0.224x | -137.84% |
| 2012-06-30 | AU$-1.79 Million ≈ $-1.26 Million |
AU$-1.06 Million ≈ $-749.33K |
0.593x | -38.23% |
| 2011-06-30 | AU$-832.03K ≈ $-588.72K |
AU$-798.32K ≈ $-564.86K |
0.959x | +128.20% |
| 2010-06-30 | AU$278.83K ≈ $197.29K |
AU$-948.56K ≈ $-671.16K |
-3.402x | -273.69% |
| 2009-06-30 | AU$-604.48K ≈ $-427.71K |
AU$-1.18 Million ≈ $-837.69K |
1.959x | +111.72% |
| 2008-06-30 | AU$73.05K ≈ $51.69K |
AU$-1.22 Million ≈ $-863.74K |
-16.710x | -590.36% |
| 2007-06-30 | AU$1.77 Million ≈ $1.25 Million |
AU$-4.28 Million ≈ $-3.03 Million |
-2.421x | -15.33% |
| 2006-06-30 | AU$2.03 Million ≈ $1.43 Million |
AU$-4.25 Million ≈ $-3.01 Million |
-2.099x | -111.44% |
| 2005-06-30 | AU$2.83 Million ≈ $2.00 Million |
AU$-2.81 Million ≈ $-1.99 Million |
-0.993x | +4.43% |
| 2004-06-30 | AU$3.64 Million ≈ $2.57 Million |
AU$-3.78 Million ≈ $-2.67 Million |
-1.039x | +69.18% |
| 2003-06-30 | AU$953.60K ≈ $674.73K |
AU$-3.21 Million ≈ $-2.27 Million |
-3.369x | -105.38% |
| 2002-06-30 | AU$1.46 Million ≈ $1.03 Million |
AU$-2.39 Million ≈ $-1.69 Million |
-1.641x | -165.89% |
| 2001-06-30 | AU$3.61 Million ≈ $2.56 Million |
AU$-2.23 Million ≈ $-1.58 Million |
-0.617x | +64.76% |
| 2000-06-30 | AU$1.28 Million ≈ $903.24K |
AU$-2.23 Million ≈ $-1.58 Million |
-1.751x | -281.36% |
| 1999-06-30 | AU$2.68 Million ≈ $1.89 Million |
AU$-1.23 Million ≈ $-869.86K |
-0.459x | +58.73% |
| 1998-06-30 | AU$1.17 Million ≈ $830.02K |
AU$-1.30 Million ≈ $-923.14K |
-1.112x | +96.97% |
| 1997-06-30 | AU$24.34K ≈ $17.22K |
AU$-893.39K ≈ $-632.13K |
-36.710x | -311.58% |
| 1996-06-30 | AU$-41.55K ≈ $-29.40K |
AU$-720.86K ≈ $-510.06K |
17.351x | +23.87% |
| 1995-06-30 | AU$-134.00K ≈ $-94.81K |
AU$-1.88 Million ≈ $-1.33 Million |
14.007x | +810.95% |
| 1994-06-30 | AU$336.00K ≈ $237.74K |
AU$-662.00K ≈ $-468.41K |
-1.970x | -161.86% |
| 1993-06-30 | AU$546.00K ≈ $386.33K |
AU$1.74 Million ≈ $1.23 Million |
3.185x | +623.82% |
| 1991-06-30 | AU$1.66 Million ≈ $1.17 Million |
AU$730.00K ≈ $516.52K |
0.440x | -- |
About Prescient Therapeutics Ltd
Prescient Therapeutics Limited, a clinical stage oncology company, develops drugs for the treatment of haematological and solid cancers in Australia. Its lead drug candidate is PTX-100, a first in class targeted therapy which can disrupt the RAS family pathway by inhibiting the prenylation action of the enzyme GGT-1. The company was formerly known as Virax Holdings Limited and changed its name to… Read more